Dapagliflozin for the treatment of heart failure with reduced ejection fraction in Brazil: a cost-effectiveness analysis
This study was supported by the National Institute of Science and Technology for Health Technology Assessment (Instituto de Avaliação de Tecnologias em Saúde-IATS).
Authors
- Ivan Ricardo Zimmermann (ORCID: https://orcid.org/0000-0001-7757-7519)
- Angélica Amorim Amato (ORCID: https://orcid.org/0000-0002-8454-5504)
- Henry Maia Peixoto (ORCID: https://orcid.org/0000-0001-5982-8855)
- Marcelo Andery Naves
Institutions
- Universidade de Brasília (BR)
- Brazilian Society of Tropical Medicine (BR)
Publication Details
- Journal
- The Lancet Regional Health - Americas
- Published
- 2024-12-28
- DOI
- https://doi.org/10.1016/j.lana.2024.100968
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.36